Halozyme Therapeutics (NASDAQ:HALO) changed -2.04% to recent value of $17.73. The stock transacted 799387 shares during most recent day however it has an average volume of 1.66M shares. It spotted trading -10.14% off 52-week high price. On the other end, the stock has been noted 28.11% away from the low price over the last 52-weeks.
On Jan. 03, 2020, Halozyme Therapeutics (NASDAQ:HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m. ET. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
Halozyme Therapeutics is a biotechnology company focused on novel biological and drug delivery approaches. Halozyme’s proprietary enzyme rHuPH20 is used to facilitate the delivery of injected drugs and fluids and potentially reduce the treatment burden of other drugs to patients. Halozyme has licensed its rHuPH20 technology, called ENHANZE®, to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
HALO has a gross margin of 83.00% and an operating margin of -17.70% while its profit margin remained -19.70% for the last 12 months. Its earnings per share (EPS) expected to touch remained -223.50% for this year while earning per share for the next 5-years is expected to reach at 24.00%.
The company has 147.91M of outstanding shares and 138.03M shares were floated in the market. According to the most recent quarter its current ratio was 3.2 that represents company’s ability to meet its current financial obligations. The price moved ahead of -4.75% from the mean of 20 days, -0.62% from mean of 50 days SMA and performed 6.65% from mean of 200 days price. Company’s performance for the week was -3.06%, -5.14% for month.